Changes in weight and BMI with first-line doravirine-based therapy.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
pubmed:
14
10
2020
medline:
3
3
2021
entrez:
13
10
2020
Statut:
ppublish
Résumé
To evaluate changes in weight and BMI in adults with HIV-1 at 1 and 2 years after starting an antiretroviral regimen that included doravirine, ritonavir-boosted darunavir, or efavirenz. Post-hoc analysis of pooled data from three randomized controlled trials. We evaluated weight change from baseline, weight gain at least 10%, and increase in BMI after 48 and 96 weeks of treatment with doravirine, ritonavir-boosted darunavir, or efavirenz-based regimens. Risk factors for weight gain and metabolic outcomes associated with weight gain were also examined. Mean (and median) weight changes were similar for doravirine [1.7 (1.0) kg] and ritonavir-boosted darunavir [1.4 (0.6) kg] and were lower for efavirenz [0.6 (0.0) kg] at week 48 but were similar across all treatment groups at week 96 [2.4 (1.5), 1.8 (0.7), and 1.6 (1.0) kg, respectively]. No significant differences between treatment groups were found in the proportion of participants with at least 10% weight gain or the proportion with BMI class increase at either time point. Low CD4 T-cell count and high HIV-1 RNA at baseline were associated with at least 10% weight gain and BMI class increase at both timepoints, but treatment group, age, sex, and race were not. Weight gains over 96 weeks were low in all treatment groups and were similar to the average yearly change in adults without HIV-1. Significant weight gain and BMI class increase were similar across the treatment groups and were predicted by low baseline CD4 T-cell count and high baseline HIV-1 RNA.
Identifiants
pubmed: 33048879
doi: 10.1097/QAD.0000000000002725
pii: 00002030-202101010-00010
pmc: PMC7752237
doi:
Substances chimiques
Anti-HIV Agents
0
Pyridones
0
Triazoles
0
doravirine
913P6LK81M
Ritonavir
O3J8G9O825
Darunavir
YO603Y8113
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-99Références
Hutfless S, Maruthur NM, Wilson RF, Gudzune KA, Brown R, Lau B, et al. Strategies to prevent weight gain among adults . Rockville, MD: Agency for Healthcare Research and Quality (US); 2013.
World Health Organization. Overweight and obesity, key facts. Available at: www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [accessed January 2020].
Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016 . Available at: https://www.cdc.gov/nchs/data/databriefs/db288.pdf [accessed Feb 2020].
Haslam CM, James WP. Obesity . Lancet 2005; 366:1197–1209.
Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications . Hepatology 2010; 51:679–689.
Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality . Clin Infect Dis 2015; 60:1852–1859.
Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study . HIV Med 2016; 17:255–268.
Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of prediabetes, diabetes mellitus, cardiovascular disease, and mortality . Front Endocrinol (Lausanne) 2018; 9:705.
Mohr R, Boesecke C, Dold L, Schierwagen R, Schwarze-Zander C, Wasmuth JC, et al. Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis . Medicine (Baltimore) 2018; 97:e0462.
Lemoine M, Lacombe K, Bastard JP, Sébire M, Fonquernie L, Valin N, et al. Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients . AIDS 2017; 31:1955–1964.
Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada . AIDS Res Hum Retroviruses 2016; 32:50–58.
Hasse B, Iff M, Ledergerber B, Calmy A, Schmid P, Hauser C, et al. Obesity trends and body mass index changes after starting antiretroviral treatment: the Swiss HIV Cohort Study . Open Forum Infect Dis 2014; 32:ofu040.
Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf M-C, et al. HIV infection and obesity: where did all the wasting go? . Antivir Ther 2012; 17:1281–1289.
Crum-Cianflone N, Roediger MP, Eberly L, Headd M, Marconi V, Ganesan A, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic . PLoS One 2010; 5:e10106.
Bakal DR, Coelho LE, Luz PM, Clark JL, De Boni RB, Cardoso SW, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors . J Antimicrob Chemother 2018; 73:2177–2185.
Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons . AIDS Res Hum Retroviruses 2013; 29:435–440.
Bares SH, Smeaton LM, Xu A, Godfrey C, McComsey GA. HIV-infected women gain more weight than HIV-infected men following the initiation of antiretroviral therapy . J Womens Health (Larchmt) 2018; 27:1162–1169.
Thompson-Paul AM, Wei SC, Mattson CL, Robertson M, Hernandez-Romieu AC, Bell TK, Skarbinski J. Obesity among HIV-infected adults receiving medical care in the United States: data from the cross-sectional medical monitoring project and national health and nutrition examination survey . Medicine (Baltimore) 2015; 94:e1081.
Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? . J Virus Erad 2019; 5:41–43.
Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials . Clin Infect Dis 2019; 71:1379–1389.
Kerchberger AM, Sheth AN, Angert CD, Mehta CC, Summers NA, Ofotokun I, et al. Weight gain associated with integrase stand transfer inhibitor use in women . Clin Infect Dis 2019; 71:593–600.
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV . N Engl J Med 2019; 381:803–815.
Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, et al. NAMSAL ANRS 12313 Study Group. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1 . N Engl J Med 2019; 381:816–826.
McMahon C, Trevaskis JL, Carter CC, Holsapple K, White K, Das M, et al. Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight . PLoS One 2020; 15:e0229617.
Gorwood J, Bourgeois C, Pourcher V, Pourcher G, Charlotte F, Mantecon M, et al. The integrase inhibitors dolutegravir and raltegravir exert pro-adipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes . Clin Infect Dis 2020. ciaa259doi: 10.1093/cid/ciaa259. [Epub ahead of print].
doi: 10.1093/cid/ciaa259.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, noninferiority trial . Lancet HIV 2018; 5:e211–e220.
Orkin C, Squires KE, Molina JM, Sax PE, Wong W-W, Sussmann O, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is noninferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial . Clin Infect Dis 2019; 68:535–544.
Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arastéh K, Hoffmann C, et al. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial . Antivir Ther 2019; 24:425–435.
Johnson M, Kumar P, Molina JM, Rizzardini G, Cahn P, Bickel M, et al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial . J Acquir Immune Defic Syndr 2019; 81:463–472.
Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy . Clin Infect Dis 2020; 70:1267–1274.
Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, et al. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density . AIDS 2013; 27:2069–2079.
Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to nonnucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada . J Int AIDS Soc 2020; 23:e25484.
Paisible AL, Chang CC, So-Armah KA, Butt AA, Leaf DA, Budoff M, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction . J Acquir Immune Defic Syndr 2015; 68:209–216.
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease . J Clin Endocrinol Metab 2007; 92:2506–2512.
Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population . Clin Infect Dis 2003; 37:292–298.
Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women . Clin Infect Dis 2007; 45:1074–1081.
Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals . J Acquir Immune Defic Syndr 2003; 33:506–512.